Sarah James • Cantor Fitzgerald

Answer

Chief Financial Officer Vinay Bassi explained that current efficiency initiatives are more complex than previous ones and are expected to yield low single-digit millions in run-rate savings, starting in Q4, with a long-term goal of reaching mid-twenties EBITDA margins. President and CEO Chris Fowler addressed the legislative impact, noting that while there could be a short-term headwind on sales as hospitals plan, he sees a long-term opportunity for TruBridge to help clients navigate the new environment.

Ask Fintool Equity Research AI

Answer

CEO Peter Anevski confirmed the dynamic was due to higher expected utilization rates based on the industry mix of the early client wins. He also stated that demand for Progyny's benefits continues to increase across companies of all sizes, consistent with trends seen in prior years.

Ask Fintool Equity Research AI

Answer

CEO Peter Anevski reiterated that the company plans for roughly $15 million in incremental P&L investments this year related to its platform, product expansion, and recent acquisitions, but declined to provide a specific breakdown between hiring and other costs. Regarding tariffs, he stated that he does not anticipate an impact on the timing of drug shipments and could not speculate further.

Ask Fintool Equity Research AI

Answer

CEO Peter Anevski confirmed there was no demand pull-forward in Q4 and none is assumed for 2025, as the transition program is limited to members already in treatment. Both he and CFO Mark Livingston noted the financial impact of new services is currently too small to model separately but pledged to provide more detail once it becomes material.

Ask Fintool Equity Research AI

Answer

CEO Pete Anevski clarified the client math, stating there were only 5 client losses during the year and that some new clients had already gone live. He firmly stated that Progyny does not believe in or offer plans with arbitrary restrictions like dollar maximums, as they create a poor member experience and lead to suboptimal clinical decisions driven by 'economic scarcity.'

Ask Fintool Equity Research AI

Answer

CFO Marc Benathen stated that RexMD CACs were temporarily up 15-25% sequentially due to competitive spending, which prompted a pullback in marketing volume. He confirmed that proactive adjustments have returned CACs to historical levels. CEO Justin Schreiber added that the team's intense focus on the weight management business transition contributed to a slower response but affirmed his confidence in RexMD's long-term trajectory.

Ask Fintool Equity Research AI

Answer

CFO Marc Benathen detailed that the EBITDA guidance consists of approximately $20 million from telehealth and $10-12 million from WorkSimpli, with the increase driven primarily by revenue growth and operating leverage in both segments, not one-time cost removals. He noted that revenue from new insured lives is expected to be a small, mid-single-digit percentage of total revenue in 2025 as the company focuses on building scale. However, he projected it could grow to represent 30-50% of revenue within the next 3-4 years as the LifeMD+ offering and subscriber base expand.

Ask Fintool Equity Research AI

Answer

CFO Marc Benathen attributed the Q3 margin strength to strong retention, upselling longer subscriptions, and a higher mix of service-based revenue from weight management. He expects margins to remain stable with potential improvements from the new pharmacy. Executive Justin Schreiber added that the company is strategically adding FTEs but is comfortable with current staffing levels, citing a strong culture and potential partnerships to augment their provider group if needed.

Ask Fintool Equity Research AI

Answer

CFO Marc Benathen attributed the earnings beat primarily to stronger-than-expected retention revenue from existing patients, which he noted is largely sustainable. He also mentioned a small, Q1-specific benefit from pent-up demand in weight management acquisitions. CEO Justin Schreiber confirmed the compounding pharmacy is on track to be licensed in the summer and available in most states by year-end, while the existing mail-order pharmacy is scaling well, averaging nearly 1,000 prescriptions daily.

Ask Fintool Equity Research AI

Answer

CEO Eric Evans stated that while it is too early to precisely quantify the opportunity, the proposal is a significant positive. He emphasized that removing procedural barriers for physicians is powerful, as it simplifies their workflow and encourages them to bring more commercial cases, similar to the trend seen after total joints were approved for ASCs. He noted these are higher-acuity procedures and part of a favorable long-term tailwind.

Ask Fintool Equity Research AI

Answer

CFO David Doherty explained that while GI volume growth was strong and contributed to rate pressure, the impact on the overall mix was marginal in basis points. He cautioned against overanalyzing a single quarter due to calendar effects and reiterated the full-year outlook for balanced growth. CEO J. Evans added that the core GI business remains a strong and valued growth driver for the company alongside orthopedics and ophthalmology.

Ask Fintool Equity Research AI

Answer

CEO J. Evans reiterated the company's focus on deleveraging and confirmed the goal to reach the 3x range remains, though short-term M&A activity could cause temporary pressure. CFO David Doherty affirmed that the 5-year model shows no need to access capital markets to fund growth. He expects the leverage ratio to continue its downward trajectory through 2025 and beyond, despite potential short-term ticks up from acquisitions, ultimately reaching the mid-3s and better.

Ask Fintool Equity Research AI

Answer

CFO Celeste Mellet confirmed that the guidance boost reflects the continuation of CenterWell's strong patient growth and pharmacy momentum, as well as better-than-expected MA membership retention. She noted that these trends are expected to continue, while certain one-time favorable items from Q1 are not being run-rated.

Ask Fintool Equity Research AI

Answer

Chief Financial Officer Celeste Mellet clarified that while the full-year investment forecast remains the same, the timing has shifted. Only about 10 basis points of the incremental investment impact flowed through the MLR in Q1, as many Stars-related investments ramped up later in the quarter. A higher impact is now expected in Q2 through Q4.

Ask Fintool Equity Research AI

Answer

CEO James Rechtin confirmed that reaching the 3% margin target necessitates a competitive Stars position, a normalized rate environment, and optimal operating performance. He described the path as a 'steady march.' CFO Celeste Mellet added that this requires better multi-year planning and ruthlessly prioritizing initiatives that drive value to create investment capacity.

Ask Fintool Equity Research AI

Answer

George Renaudin, President of the Insurance segment, explained that crosswalking is one of several levers being evaluated for Stars mitigation. CFO Susan Diamond stated that no specific 2025 MA margin guidance has been given. She noted that any margin progression was expected to come from exiting unprofitable plans, but this is now being balanced against new investment needs.

Ask Fintool Equity Research AI

Answer

CFO Mala Murthy explained that Q2 saw incremental pressure in the U.S. cash business from higher churn and fewer gross adds, which she attributed to more consumers using insurance. The updated guidance assumes these trends continue. As a result, the high end of the Q4 guidance no longer implies a return to flat year-over-year growth. The 2026 outlook depends on how effectively the new insurance offering can scale to offset these cash-pay headwinds.

Ask Fintool Equity Research AI

Answer

Chief Financial Officer Mala Murthy indicated that detailed 2025 guidance would be provided in February. She stated that the company has provided a 'ZIP code' for 2025 Integrated Care revenue growth and margins, along with color on BetterHelp's trajectory, but declined to provide more granular detail on the specific components at this time.

Ask Fintool Equity Research AI

Answer

CFO Mala Murthy deferred providing granular details, stating that the company would offer more comprehensive 2025 guidance in February. She indicated that the current commentary provides a general 'ZIP code' for full-year revenue growth and adjusted EBITDA margins for the Integrated Care segment.

Ask Fintool Equity Research AI

Answer

Executive VP & CFO Steve Filton acknowledged the 2.5-3% target has been 'elusive' partly because the company has not captured its fair share of the shift to outpatient care. However, he affirmed that with a renewed and intense focus on growing outpatient services, the company believes this long-term growth target remains reasonable as the underlying demand exists. He noted sequential improvement from Q1 to Q2 in outpatient growth.

Ask Fintool Equity Research AI

Answer

Executive Steve Filton explained the strategy is to build out the continuum of care, with a specific focus on expanding freestanding outpatient facilities and entering the opioid use disorder space as part of an integrated care model. He projected adding 10-12 freestanding facilities annually, while noting the opioid treatment pipeline has a longer, less predictable development timeline.

Ask Fintool Equity Research AI

Answer

Executive Steve Filton detailed a strategy focused on expanding the outpatient continuum of care, including developing more freestanding facilities. He confirmed expansion into the OUD space, emphasizing an integrated care model rather than standalone clinics. He projected adding 10-12 freestanding outpatient facilities annually, noting the OUD pipeline would develop more slowly.

Ask Fintool Equity Research AI

Answer

CFO Mike Marks noted that collection rates on traditional commercial plans are stable, while exchange collections are slightly lower. CEO Sam Hazen clarified that for the truly uninsured (self-pay), most patients qualify for charity care or significant discounts under HCA's patient protection policy, resulting in minimal revenue being produced or collected from this population.

Ask Fintool Equity Research AI

Answer

CEO Sam Hazen explained that HCA's capital allocation strategy remains consistent, with a significant portion of its $6.2 billion active project pipeline dedicated to increasing inpatient capacity. He clarified that capital also supports outpatient facilities, emergency rooms, cath labs, and clinical technology. Hazen stated he does not anticipate a material change in the allocation of capital across these categories, as the company continues to invest to meet high levels of occupancy and demand.

Ask Fintool Equity Research AI

Answer

CFO Mike Marks explained the moderation in volume growth guidance for 2025 is driven by several factors. The primary driver is slower growth expected from healthcare exchanges compared to the surge in 2024. Other factors include the non-repeating benefit from the Two-Midnight Rule and the flattening out of Medicaid redeterminations. He affirmed that 3-4% growth is still strong and above their long-term trend.

Ask Fintool Equity Research AI

Answer

CEO Sam Hazen explained that the decline in outpatient surgery volume was concentrated in lower-paying Medicaid and uninsured cases, which has resulted in higher revenue per case and improved profitability for the service line. He does not anticipate a significant change in this trend for 2025. CFO Mike Marks added that while HCA has business interruption coverage, they are not in a position to disclose policy limits or potential recovery amounts.

Ask Fintool Equity Research AI

Answer

CEO Sarah London responded that the company saw broad-based utilization across categories rather than a specific intra-quarter acceleration. She hypothesized that heightened media coverage about potential coverage loss drove preemptive demand from members, which was compounded by aggressive provider coding. She confirmed that the back-half forecast prudently accounts for this trend continuing.

Ask Fintool Equity Research AI

Answer

CEO Sarah London responded that while the primary driver was the overall morbidity shift, there was also broad-based utilization throughout the quarter. She did not note a specific acceleration within the quarter but explained that the company has baked in an assumption of continued elevated trend in the second half, partly due to members potentially seeking care before the possible expiration of enhanced APTCs.

Ask Fintool Equity Research AI

Answer

CEO Sarah London explained that new members are showing utilization consistent with care that informs acuity (like PCP visits), but the company is taking a prudent posture until risk adjustment data is available. She noted that effectuation was strong, renewal rates were meaningfully higher, and the year-end membership projection is now in the high 4 million range, up from mid-4s, due to the strong Q1 starting point.

Ask Fintool Equity Research AI

Answer

CEO Sarah London stated it was too early in the year to change EPS guidance but confirmed the company is still targeting a 1% margin for the PDP business and expects to be well within the 5% to 7.5% range for Marketplace. CFO Andrew Asher added that the higher revenue represents future earnings power, but its exact impact in 2025 is not yet certain.

Ask Fintool Equity Research AI

Answer

CEO Sarah London explained that the slowing of the 'rejoiner' trend, who return with high initial utilization, should provide a natural tailwind into 2025. CFO Andrew Asher added that for GLP-1s, Centene uses data from states with existing coverage to inform rate discussions with states considering adding the drugs, ensuring uptake is factored into pricing.

Ask Fintool Equity Research AI

Answer

CEO Joseph Zubretsky stated the original model for the Connecticut acquisition anticipated reaching target margins by 2027. CFO Mark Keim updated the year-end Marketplace membership forecast to approximately 650,000, up slightly due to strong SEP enrollment. He clarified that this subtle membership increase was not a primary driver of MLR pressure, as the new members' acuity profile was similar to the existing book's.

Ask Fintool Equity Research AI

Answer

CEO Joseph Zubretsky confirmed the Medicaid trend increase was "entirely due to early in the year of conservatism" and not based on Q1 data. CFO Mark Keim explained the Marketplace MLR trajectory would be flatter than usual due to a higher mix of new members, the gradual improvement of the ConnectiCare book, and a lower mix of more seasonal products.

Ask Fintool Equity Research AI

Answer

CEO Joe Zubretsky clarified that the 2024 trend of 6.5% included a significant one-time acuity shift from redeterminations; the 2025 forecast of 4.5% represents a higher 'core' utilization trend than seen in 2023. CFO Mark Keim added this 4.5% trend is matched by a 4.5% rate increase assumption. Regarding margins, Zubretsky stated that achieving the long-term target in 2025 would require the remaining 25% of unknown rates to come in above their conservative 2.5% estimate, or through un-forecasted retroactive rate adjustments.

Ask Fintool Equity Research AI

Answer

President and CEO Joe Zubretsky emphasized that Molina is comfortably operating its Medicaid business at a 90% MCR. CFO Mark Keim provided a bridge from the Q3 reported 90.5% MCR to an expected 89% in Q4. He explained that the clean Q3 jumping-off point is 90% after excluding the 50 bps California retro adjustment. The Q4 improvement is driven by the non-recurrence of the California item, known rate increases, and continued improvement in new store performance. He also guided to a full-year G&A ratio of 6.8%.

Ask Fintool Equity Research AI

Answer

Chairman & CEO Saum Sutaria responded by highlighting that the most significant factor in the quarter was the continued and successful execution of Tenet's multi-year high-acuity strategy. He emphasized that this strategy is consistently delivering strong revenue and earnings growth across the hospital portfolio.

Ask Fintool Equity Research AI

Answer

Chairman and CEO Dr. Saum Sutaria clarified the guidance was for the remainder of 2024 and highlighted that the strong revenue per case growth was achieved even after acquiring a large, lower-acuity portfolio of centers. EVP and CFO Sun Park stated that "virtually all" of the DPP revenue relates to the hospital segment due to patient and payment mix differences.

Ask Fintool Equity Research AI

Answer

CEO Andrew Witty reiterated that the outcome is unknown but emphasized the company's "mesh of protection." This includes government regulations like IRA inflation caps and Medicaid best price rules, as well as OptumRx's own contractual price protections with manufacturers. He assured that the company would be very thoughtful in its bidding process to account for these layers of protection.

Ask Fintool Equity Research AI

Answer

Executive John Rex explained the ~100 basis point increase in the 2025 MLR is driven by IRA impacts, a continued mix shift toward public sector plans, and the second year of CMS funding cuts. He noted that non-repeating negative impacts from 2024, such as the cyberattack and South America business impacts, provided a partial offset, quantifying their combined 2024 effect at about 30 basis points.

Ask Fintool Equity Research AI

Answer

Roger Connor, CEO of OptumInsight, stated that the core business is performing well and that he feels confident going into 2025. Regarding Change, he explained that some business disruption will carry into 2025 because reconnected customers are using lower volumes as they seek vendor redundancy. He framed this as an opportunity to win new business and highlighted the innovation potential from the newly modernized, AI-enabled tech environment.

Ask Fintool Equity Research AI

Answer

CFO Norman Rosenberg explained that as a self-insured entity, some fluctuation is inherent but that the company saves millions annually compared to traditional premiums. He noted that the reserving process becomes more accurate over time and this quarter's adjustment should help smooth costs going forward. He clarified that SG&A is expected to decline sequentially in absolute dollar terms throughout 2025, while as a percentage of revenue, it should improve from Q4 levels but may fluctuate quarterly before improving in the second half of the year.

Ask Fintool Equity Research AI

Answer

CFO Brian Evanko clarified that the prior commentary was directional and that the full magnitude of the stop-loss pressure was not known at the time. He identified two key items that are new since that commentary: the greater-than-anticipated stop-loss pressure and the new $150 million investment plan. He noted that underlying business growth remains strong, with top-line growth expected around 6% ex-Medicare.

Ask Fintool Equity Research AI

Answer

CEO Christopher Hunter affirmed that direct engagement can be effective, though it's not always possible to meet every source face-to-face. CFO Heather Dixon explained Q4 seasonality, confirming October is typically the strongest month before volumes soften in November and December due to the holidays.

Ask Fintool Equity Research AI